SNP-630

SNP-630 is a novel, first-in-class synthetic small molecule developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). It acts through multiple mechanisms, including inhibition of cytochrome P450 2E1 (CYP2E1) to reduce reactive oxygen species (ROS) generation, suppression of hepatic triglyceride synthesis and accumulation, and reduction in fatty acid absorption by liver cells. Additionally, SNP-630 downregulates pro-fibrotic and pro-inflammatory factors by modulating immune cells and hepatic stellate cells, while also helping maintain intestinal barrier integrity to further reduce liver inflammation. Preclinical studies in mice demonstrated improvements in liver inflammation, steatosis, fibrosis, and reductions in ALT levels. Clinical trials with its active metabolites (notably SNP-630-MS) have shown significant improvement in ALT levels and markers of fibrosis with a favorable safety profile[1][2][3][5][6][7][8].